AstraZeneca (LON:AZN)has agreed the sale and licence of the commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) in Europe and Russia to Cheplapharm..

AstraZeneca (LON:AZN) announced its year-to-date and Q3 2019 results. Year-to-date Product Sales growth of 13% (17% at CER1) to $17,315m included third-quarter Product Sales of $6,132m (+16%, +18% at CER)...

AstraZeneca (LON:AZN) announced that the US Food and Drug Administration has approved Farxiga (dapagliflozin) to reduce the risk of hospitalisation for heart failure (hHF) in adults with type-2 diabetes and..

AstraZeneca (LON:AZN) and Daiichi Sankyo Company Limited announced that the US Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for [fam-] trastuzumab deruxtecan (DS-8201)..

Fasenra is now the only respiratory biologic that offers the choice of administration at home or in a doctor’s office with eight-week maintenance dosing AstraZeneca plc (LON: AZN) has today..

AstraZeneca (LON: AZN) has agreed to sell the global commercial rights, excluding China, Japan, the US and Mexico, for Losec (omeprazole) and associated brands to Cheplapharm Arzneimittel GmbH (Cheplapharm). The..

AstraZeneca (LON: AZN) has today announced that Qtrilmet (metformin hydrochloride, saxagliptin and dapagliflozin) modified-release tablets have been recommended for marketing authorisation in the European Union for the treatment of adults..

AstraZeneca plc (LON:AZN) has amended its collaboration agreement with Ironwood Pharmaceuticals, Inc. (Ironwood) in China mainland, China Hong Kong and China Macau for Linzess* (linaclotide), a first-in-class new treatment for..

AstraZeneca plc (LON:AZN) today announced that it has received marketing authorisation from China’s National Medical Products Administration for Tagrisso as a 1st-line treatment for adults with locally-advanced or metastatic non-small..

Brilinta reduced the risk of cardiovascular events in patients with coronary artery disease and type-2 diabetes in Phase III THEMIS trial. Additionally, Brilinta showed a more favourable clinical benefit in..

AstraZeneca plc (LON:AZN) today announced detailed results from the landmark Phase III DAPA-HF trial that showed Farxiga on top of standard of care reduced both the incidence of cardiovascular death..

AstraZeneca plc (LON: AZN) today announced that the Phase III TULIP 2 trial for anifrolumab, a potential new medicine for the treatment of systemic lupus erythematosus (SLE), met its primary..

AstraZeneca plc (LON:AZN) today announced positive results from the Phase III ETHOS trial for triple-combination therapy Breztri Aerosphere, formerly PT010, in patients with moderate to very severe chronic obstructive pulmonary..

AstraZeneca plc (LON:AZN) today announced that the US Food and Drug Administration has granted Orphan Drug Designation to Fasenra (benralizumab) for the treatment of eosinophilic oesophagitis (EoE). EoE is a..

AstraZeneca plc (LON:AZN) today announced that it has agreed to buy a US Food and Drug Administration Priority Review Voucher for a total cash consideration of $95m from a subsidiary..

AstraZeneca (LON: AZN) today announced that its partner FibroGen (China) Medical Technology Development Co., Ltd. (FibroGen China) has received marketing authorisation for roxadustat in China for the treatment of anaemia..

AstraZeneca plc (LON: AZN) today announced final overall survival results from the Phase III NEPTUNE trial, a randomised, open-label, multi-centre, global trial of Imfinzi (durvalumab) in combination with tremelimumab, an..

Farxiga met primary endpoint in landmark Phase III DAPA-HF trial for the treatment of patients with heart failure DAPA-HF is the first heart failure outcomes trial with an SGLT2 inhibitor..